Custom service
Biotinylated Peptides
Biotinylate peptides at the terminus or a side chain, with or without spacers
Biotinylated Peptides supports programmes that biotinylate peptides at the terminus or a side chain, with or without spacers. In a typical engagement we plan the N-terminal and Lys biotinylation route first, confirm compatibility with PEG-spacer (LC- and Mini-) biotin options, and release biotinylated peptide with biotin-ratio assay on a 2–4 weeks schedule.
Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep N-terminal and Lys biotinylation as the primary option and hold PEG-spacer (LC- and Mini-) biotin options in reserve, so that scale-up never depends on an unproven step.
Streptavidin capture and plate-coating workflows
Pull-down and biophysical binding assays
Biotinylated material at GMP grade
Modifications requiring radiological or BSL-3 containment
Modified peptides are released against a specification that includes site occupancy. Where a modification is labile (sulfation, glycosylation, phosphorylation), we use fragmentation data rather than mass shift alone to assign the site, and we state detection limits for any positional isomers that co-elute.
Service Highlights
- N-terminal and Lys biotinylation as the default route, with PEG-spacer (LC- and Mini-) biotin options held as a proven fallback
- Desthiobiotin and Strep-tag variants worked into the design where the application requires it
- Modification sites are mapped on the sequence and confirmed by MS/MS before release
- Analytical confirmation of every intermediate before the final release
- Modified and unmodified species are separated and quantified, not just reported
- Biotinylated peptide with biotin-ratio assay delivered with a complete conjugation or synthesis certificate
How the work runs
Sequence & modification map
We annotate every modification site, protection strategy and analytical target before synthesis starts.
Solid-phase assembly
The chain is built with Fmoc chemistry, inserting modified or unnatural residues at the mapped positions.
Modification chemistry
Post-synthesis steps — N-terminal and Lys biotinylation, PEG-spacer (LC- and Mini-) biotin options — are run under conditions validated on a test cleavage.
Cleavage & purification
Global deprotection and cleavage are followed by RP-HPLC purification to the agreed purity.
Analytical release
Purity, identity and modification ratio are confirmed by HPLC, MS and MS/MS site mapping.
Documentation
Biotinylated peptide with biotin-ratio assay is released with the batch record and analytical package after QC sign-off.
Specifications & timeline
- Turnaround
- 2–4 weeks
- Typical scale
- 0.5 mg – 1 g modified peptide
- Chemistry options
- N-terminal and Lys biotinylation; PEG-spacer (LC- and Mini-) biotin options; desthiobiotin and Strep-tag variants
- Deliverable
- Biotinylated peptide with biotin-ratio assay
- QC package
- HPLC purity, ESI/MALDI MS, MS/MS site mapping, modification ratio
- Shipping
- Ambient or blue ice as stability data dictate
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.